ClinicalTrials.gg
CompletedNCT00969709Updated Oct 25, 2013Results posted

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

A Phase 3 interventional study of Levomilnacipran ER and Levomilnacipran ER in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 38 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-10-25.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
724
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
3rd of 14
724 · median 472
Started
2009
with 3 others
Phase 3
10 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
9 of 14
Forest Laboratories

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is one of 4 that started in 2009, is one of 10 in phase 3, and was the 1st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-65 years old
  • Currently meet the criteria for Major Depressive Disorder
  • The patient's current depressive episode must be at least 8 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women with who are not practicing a reliable method of
  • Patients with a history of meeting criteria for:

    • any manic or hypomanic episode
    • schizophrenia or any other psychotic disorder
    • obsessive-compulsive disorder
  • Patients who are considered a suicide risk
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
724 participants (actual)

Study arms

  • Experimental
    1

    40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.

    Drug: Levomilnacipran ER

  • Experimental
    2

    80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing

    Drug: Levomilnacipran ER

  • Experimental
    3

    120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing

    Drug: Levomilnacipran ER

  • Placebo comparator
    4

    Matching placebo capsules, oral administration, once daily.

    Drug: Placebo

Interventions

  • Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.

  • Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.

  • Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.

  • DrugPlacebo

    Matching placebo capsules, oral administration, once daily for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity for all measured symptoms).

    Time frame: From Baseline to Week 8

Secondary outcomes

  1. Change in Sheehan Disability Scale (SDS) Total Score

    The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate functional impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe for all measured symptoms)

    Time frame: From Baseline to Week 8

07

Results

Posted Oct 25, 2013

Participant flow

Patient recruitment at 38 study centers located in the United States during a 17 month period from September 2009 to February 2011.

Participant flow — Overall Study
MilestonePlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mg
Started176178179180
Completed138130121117
Not completed38485863
Withdrew: Adverse event3132612
Withdrew: Lack of efficacy7413
Withdrew: Protocol violation95910
Withdrew: Withdrawal by subject9121123
Withdrew: Lost to follow-up1014815
Withdrew: Other reasons0030

Outcome measures

PrimaryChange in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity for all measured symptoms).

Time frame:
From Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
Units on a scalePlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mg
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-11.6 ± 0.97-14.8 ± 0.99-15.6 ± 1.00-16.5 ± 1.02
Statistical analysis
  • Placebo vs Levomilnacipran ER 40 mg · Mixed Models Analysis · p = 0.0186 · Least squares mean difference: -3.23 · 95% CI -5.92 to -0.54Mixed-effects model for repeated measures.
  • Placebo vs Levomilnacipran ER 80 mg · Mixed Models Analysis · p = 0.0038 · Least squares mean difference: -3.99 · 95% CI -6.69 to -1.29Mixed-effects model for repeated measures.
  • Placebo vs Levomilnacipran ER 120 mg · Mixed Models Analysis · p = 0.0005 · Least squares mean difference: -4.86 · 95% CI -7.59 to -2.12Mixed-effects model for repeated measures.
SecondaryChange in Sheehan Disability Scale (SDS) Total Score

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate functional impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe for all measured symptoms)

Time frame:
From Baseline to Week 8
Reported as:
Mean · units on a scale
Change in Sheehan Disability Scale (SDS) Total Score
units on a scalePlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mg
Change in Sheehan Disability Scale (SDS) Total Score-7.2 ± 0.74-8.6 ± 0.75-9.7 ± 0.77-9.7 ± 0.78
Statistical analysis
  • Placebo vs Levomilnacipran ER 40 mg · Mixed Models Analysis · p = 0.1687 · Least squares mean difference: -1.41 · 95% CI -3.42 to 0.60Mixed-effects model for repeated measures.
  • Placebo vs Levomilnacipran ER 80 mg · Mixed Models Analysis · p = 0.0151 · Least squares mean difference: -2.51 · 95% CI -4.54 to -0.49Mixed-effects model for repeated measures.
  • Placebo vs Levomilnacipran ER 120 mg · Mixed Models Analysis · p = 0.0141 · Least squares mean difference: -2.57 · 95% CI -4.62 to -0.52Mixed-effects model for repeated measures.

Adverse events

Collected over Adverse event data was collected over a 20 month period from September 2009 to June 2011 at 38 study sites.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/176 (0.6%)66/176 (37.5%)
Levomilnacipran ER 40 mg—3/178 (1.7%)110/178 (61.8%)
Levomilnacipran ER 80 mg—2/179 (1.1%)122/179 (68.2%)
Levomilnacipran ER 120 mg—1/180 (0.6%)112/180 (62.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mg
Premature babyPregnancy, puerperium and perinatal conditions0/1080/1220/1111/106
Small for dates babyPregnancy, puerperium and perinatal conditions0/1080/1220/1111/106
Pre-eclampsiaPregnancy, puerperium and perinatal conditions0/1080/1221/1110/106
PneumoniaInfections and infestations1/1760/1780/1790/180
AggressionPsychiatric disorders0/1761/1780/1790/180
Chest PainGeneral disorders0/1761/1780/1790/180
Deep vein thrombosisVascular disorders0/1761/1780/1790/180
Suicide AttemptPsychiatric disorders0/1761/1780/1790/180
Cytomegalovirus mononucleosisInfections and infestations0/1760/1781/1790/180
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mg
NauseaGastrointestinal disorders4/17619/17839/17923/180
HeadacheNervous system disorders20/17629/17836/17927/180
Dry mouthGastrointestinal disorders17/17620/17812/17927/180
HyperhidrosisSkin and subcutaneous tissue disorders4/1769/17824/17910/180
ConstipationGastrointestinal disorders7/17619/17818/17923/180
Heart rate increasedInvestigations3/17618/17811/17917/180
DizzinessNervous system disorders8/17610/17817/17914/180
Erectile dysfunctionReproductive system and breast disorders2/683/562/687/74
Upper respiratory tract infectionInfections and infestations10/17614/17811/1794/180
NasopharyngitisInfections and infestations10/17611/1789/1797/180

Baseline characteristics

A total of 724 patients were randomized to receive double-blind treatment (Randomized Population); 713 patients received at least 1 dose of treatment (Safety Population). The demographic analyses of the baseline participants is based on the Safety Population

Age Continuous
Age Continuous(years)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
Mean43.1 ± 11.341.6 ± 13.141.0 ± 12.840.3 ± 11.941.1 ± 12.3
Age, Customized
Age, Customized(participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
18 years to 19 years12429
20 years to 29 years31434442160
30 years to 39 years47343338152
40 years to 49 years44364846174
50 years to 59 years46483641171
60 years to 65 years715141147
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
Female108122111106447
Male68566874266
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
White134133129130526
Black or African American29363941145
Asian835319
American Indian or Alaska native10214
Native Hawaiian or other Pacific Islander00011
Other364417
Hispanic or Latino2022282292
Not Hispanic or Latino156155151158620
Region of Enrollment
Region of Enrollment(participants)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
United States176178179180713
Weight
Weight(kg)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
Mean83.8 ± 19.379.5 ± 17.183.0 ± 17.384.2 ± 18.682.6 ± 18.1
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilograms Per Meter Squared)PlaceboLevomilnacipran ER 40 mgLevomilnacipran ER 80 mgLevomilnacipran ER 120 mgTotal
Mean29.0 ± 5.828.0 ± 5.328.9 ± 5.429.2 ± 5.428.8 ± 5.5
08

Study locations

38 sites
  • Forest Investigative Site
    Phoenix, Arizona 85020, United States
  • Forest Investigative Site
    Scottsdale, Arizona 85254, United States
  • Forest Investigative Site
    Beverly Hills, California 90210, United States
  • Forest Investigative Site
    Costa Mesa, California 92626, United States
  • Forest Investigative Site
    Escondido, California 92025, United States
  • Forest Investigative Site
    Oceanside, California 92056, United States
  • Forest Investigative Site
    Sherman Oaks, California 91403, United States
  • Forest Investigative Site
    Denver, Colorado 80239, United States
  • Forest Investigative Site
    Cromwell, Connecticut 06416, United States
  • Forest Investigative Site
    Coral Springs, Florida 33067, United States
  • Forest Investigative Site
    Fort Myers, Florida 33912, United States
  • Forest Investigative Site
    Hallandale Beach, Florida 33009, United States
  • Forest Investigative Site
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site
    Orlando, Florida 32806, United States
  • Forest Investigative Site
    West Palm Beach, Florida 33407, United States
  • Forest Investigative Site
    Hoffman Estates, Illinois 60169, United States
  • Forest Investigative Site
    Wichita, Kansas 67206, United States
  • Forest Investigative Site
    Baltimore, Maryland 21285, United States
  • Forest Investigative Site
    Rockville, Maryland 20852, United States
  • Forest Investigative Site
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site
    Willingboro, New Jersey 08046, United States
  • Forest Investigative Site
    Brooklyn, New York 11235, United States
  • Forest Investigative Site
    Mt. Kisco, New York 10549, United States
  • Forest Investigative Site
    New York, New York 10003, United States
  • Forest Investigative Site
    New York, New York 10021, United States
  • Forest Investigative Site
    Staten Island, New York 10312, United States
  • Forest Investigative Site
    Raleigh, North Carolina 27607, United States
  • Forest Investigative Site
    Canton, Ohio 44718, United States
  • Forest Investigative Site
    Portland, Oregon 97210, United States
  • Forest Investigative Site
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site
    Norristown, Pennsylvania 19403, United States
  • Forest Investigative Site
    Lincoln, Rhode Island 02865, United States
  • Forest Investigative Site
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site
    Dallas, Texas 75230, United States
  • Forest Investigative Site
    Dallas, Texas 75231, United States
  • Forest Investigative Site
    San Antonio, Texas 78229, United States
  • Forest Investigative Site
    Bellevue, Washington 98007, United States
  • Forest Investigative Site
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord. 2015 Jun 11;17(3):10.4088/PCC.14m01753. doi: 10.4088/PCC.14m01753. eCollection 2015. PubMed 26644957 ↗
  • Blum SI, Tourkodimitris S, Ruth A. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. J Affect Disord. 2015 Jan 1;170:230-6. doi: 10.1016/j.jad.2014.09.005. Epub 2014 Sep 10. PubMed 25259674 ↗
  • Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013 Mar;74(3):242-8. doi: 10.4088/JCP.12m08197. PubMed 23561229 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 2 years 5 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2009
First posted
Sep 1, 2009
Start
Sep 2009
Primary completionActual
May 2011
Results delay requested
Jul 8, 2011
Results first posted
Oct 25, 2013
Last update
Oct 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00969709
Responsible party
Sponsor
First posted
Sep 1, 2009
Start date
Sep 2009
Primary completion
May 2011
Results posted
Oct 25, 2013
Last update
Oct 25, 2013

Study contacts

Carl Gommoll, MS
study director · Forest Research Institute, a subsidiary of Forest Laboratories Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion